IL307312A - Materials and methods for redirecting immune effector cells - Google Patents

Materials and methods for redirecting immune effector cells

Info

Publication number
IL307312A
IL307312A IL307312A IL30731223A IL307312A IL 307312 A IL307312 A IL 307312A IL 307312 A IL307312 A IL 307312A IL 30731223 A IL30731223 A IL 30731223A IL 307312 A IL307312 A IL 307312A
Authority
IL
Israel
Prior art keywords
redirection
materials
methods
effector cells
immune effector
Prior art date
Application number
IL307312A
Other languages
English (en)
Hebrew (he)
Inventor
Xiefan Lin-Schmidt
Ian White
Adam Zwolak
Rajkumar Ganesan
Jason Ho
Original Assignee
Janssen Biotech Inc
Lin Schmidt Xiefan
Ian White
Adam Zwolak
Rajkumar Ganesan
Jason Ho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Lin Schmidt Xiefan, Ian White, Adam Zwolak, Rajkumar Ganesan, Jason Ho filed Critical Janssen Biotech Inc
Publication of IL307312A publication Critical patent/IL307312A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL307312A 2021-03-31 2022-03-30 Materials and methods for redirecting immune effector cells IL307312A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163168605P 2021-03-31 2021-03-31
US202163168611P 2021-03-31 2021-03-31
US202163168621P 2021-03-31 2021-03-31
US202163168618P 2021-03-31 2021-03-31
US202163168628P 2021-03-31 2021-03-31
PCT/US2022/022500 WO2022212470A2 (en) 2021-03-31 2022-03-30 Materials and methods for immune effector cells redirection

Publications (1)

Publication Number Publication Date
IL307312A true IL307312A (en) 2023-11-01

Family

ID=83459998

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307312A IL307312A (en) 2021-03-31 2022-03-30 Materials and methods for redirecting immune effector cells

Country Status (11)

Country Link
US (1) US20240182582A1 (https=)
EP (1) EP4314080A4 (https=)
JP (1) JP2024512135A (https=)
KR (1) KR20230163485A (https=)
AU (1) AU2022246607A1 (https=)
BR (1) BR112023020249A2 (https=)
CA (1) CA3214963A1 (https=)
IL (1) IL307312A (https=)
MX (1) MX2023011645A (https=)
TW (1) TW202304992A (https=)
WO (1) WO2022212470A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250017240A (ko) * 2022-05-27 2025-02-04 사노피 FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions
WO2025122929A1 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. Gprc5d antibodies with enhanced effector function and uses thereof
WO2025137555A1 (en) * 2023-12-20 2025-06-26 Omniab, Inc. Polypeptides that bind to nkp46

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2007048186A1 (en) * 2005-10-25 2007-05-03 Baker Medical Research Institute Leukocyte-binding polypeptides and uses thereof
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
WO2011085178A1 (en) * 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
CA2875543A1 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
US11227669B2 (en) * 2014-06-21 2022-01-18 Norbert Ikechukwu Nwankwo Computer aided drug resistance calculator calculating drug resistance using amprenavir as a case study
JP6822849B2 (ja) * 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
AU2017237543B2 (en) * 2016-03-23 2020-02-06 Institut Pasteur Korea Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
AU2018219887B2 (en) * 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110461361A (zh) * 2017-02-10 2019-11-15 蜻蜓治疗公司 结合bcma、nkg2d和cd16的蛋白
JP7350756B2 (ja) * 2018-02-14 2023-09-26 アバ セラピューティクス アーゲー 抗ヒトｐｄ－ｌ２抗体
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
CA3099308A1 (en) * 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
HRP20240821T1 (hr) * 2018-08-27 2024-09-27 Affimed Gmbh Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
BR112022001368A2 (pt) * 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
CA3248329A1 (en) * 2019-07-31 2025-11-29 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
CN110903402B (zh) * 2019-11-27 2023-02-28 中国药科大学 一种双特异性融合蛋白及其构建方法与应用

Also Published As

Publication number Publication date
TW202304992A (zh) 2023-02-01
MX2023011645A (es) 2023-12-14
KR20230163485A (ko) 2023-11-30
EP4314080A4 (en) 2025-06-04
BR112023020249A2 (pt) 2023-12-19
US20240182582A1 (en) 2024-06-06
JP2024512135A (ja) 2024-03-18
WO2022212470A3 (en) 2022-11-17
AU2022246607A1 (en) 2023-11-16
CA3214963A1 (en) 2022-10-06
WO2022212470A2 (en) 2022-10-06
EP4314080A2 (en) 2024-02-07
WO2022212470A9 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
IL307312A (en) Materials and methods for redirecting immune effector cells
IL289830A (en) A transgenic effector training cell and its use
EP4086342A4 (en) MODIFIED IMMUNE EFFECTOR CELL AND PREPARATION METHOD THEREFOR
EP3775228A4 (en) ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE
EP4089174A4 (en) MODIFIED IMMUNE CELL AND USE THEREOF
EP3277321A4 (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
EP4294840A4 (en) ANTI-CD30L ANTIBODIES AND USES THEREOF
EP3990479A4 (en) METHODS AND MATERIALS FOR TARGETED EXPANSION OF IMMUNE EFFECTIVE CELLS
GB202111039D0 (en) Materials and methods
EP4257676A4 (en) MODIFIED IMMUNE CELL AND ITS USE
GB202101160D0 (en) Materials and methods
EP4227316A4 (en) T CELL RECEPTOR, IMMUNE CELL COMPRISING T CELL RECEPTOR, AND METHOD USING THE SAME
HK40071065A (en) Immune effector cell engineering and use thereof
HK40121928A (en) Immune effector cell and use thereof
CA3291926A1 (en) Immune effector cell and use thereof
HK40109954A (en) Nr4a3-deficient immune cells and uses thereof
HK40046590A (en) Engineered immune effector cells and use thereof
HK40117802A (en) Modified immune cells and methods of using the same
HK40086570A (en) Transgenic immune effector cell and use thereof
AU2021900927A0 (en) Materials and methods
EP4602168A4 (en) Modified immune cells and uses thereof
HK40110011A (en) Car-expressing immune cells that specifically target mesothelin and uses thereof
HK40071123A (en) Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
HK40071068A (en) Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
CA3270561A1 (en) Modified immune cells and uses thereof